Abstract
Recent development of biologic disease-modifying anti-rheumatic drugs (DMARDs) has led to better control of disease activity among patients with chronic rheumatological diseases. Many patients with rheumatic disease are living longer, adding to the growing elderly population. Rheumatic diseases, most notably rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are known to increase the risk of cognitive impairment. Systemic inflammation associated with chronic rheumatological diseases has been postulated to be key driver of cognitive decline. Recent development of classic and biologic DMARDs have led to better control of disease activity among patients with rheumatic conditions. It is proposed that strict control of systemic inflammation will significantly lower the risk of cognitive impairment among patients with rheumatic disease. The impact of classic DMARDs on cognitive function appears to be variable. On the other hand, biologic DMARDs, specifically antitumor necrosis factor (TNF) drugs (i.e., etanercept), have been shown to significantly lower the risk of dementia. Experimental studies on IL-1, IL-6, and B and T cell blockade are promising. However, clinical data is limited. Preclinical studies on targeted therapies, specifically JAK/STAT inhibitors, also show promising results. Additional studies are necessary to better understand the impact of these newer biologic agents on cognitive function in elderly patients with rheumatic disease.
Key points • Patients with chronic rheumatic conditions are beginning to live longer, adding to the elderly population. • Patients with chronic rheumatologic disease are at increased risk of cognitive impairment compared to the general population. • Recent development of biologic (i.e., TNF, IL-1, IL-6) and targeted drugs (i.e., Janus kinase inhibitors) have led to better control of disease activity. • Current evidence suggests that TNF inhibitors may have beneficial effects on cognitive function. However, evidence on newer biologic and targeted therapies is limited. |
Similar content being viewed by others
References
Boonen A, van de Rest J, Dequeker J, van der Linden S (1997) How Renoir coped with rheumatoid arthritis. Bmj. 315(7123):1704–1708. https://doi.org/10.1136/bmj.315.7123.1704
Lahaye C, Tatar Z, Dubost JJ, Soubrier M (2015) Overview of biologic treatments in the elderly. Jt Bone Spine 82(3):154–160. https://doi.org/10.1016/j.jbspin.2014.10.012
Hugo J, Ganguli M (2014) Dementia and cognitive impairment: epidemiology, diagnosis, and treatment clinics in geriatric medicine. Clin Geriatr Med 30(3):421–442. https://doi.org/10.1016/j.cger.2014.04.001
Shin SY, Katz P, Wallhagen M, Julian L (2012) Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res 64(8):1144–1150. https://doi.org/10.1002/acr.21683
Lee JH, Kim GT, Kim YK, Lee SG (2018) Cognitive function of patients with rheumatoid arthritis is associated with disease activity but not carotid atherosclerotic changes. Clin Exp Rheumatol 36(5):856–861
Murray SG, Yazdany J, Kaiser R, Criswell LA, Trupin L, Yelin EH, Katz PP, Julian LJ (2012) Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res 64(9):1328–1333. https://doi.org/10.1002/acr.21691
Hanly JG, Hong C, Smith S, Fisk JD (1999) A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42(4):728–734. https://doi.org/10.1002/1529-0131(199904)42:4<728::AID-ANR16>3.0.CO;2-O
Jagpal A, Navarro-Millán I (2018) Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2(1):10. https://doi.org/10.1186/s41927-018-0014-y
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732. https://doi.org/10.1002/art.20878
Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford, England) 52(1):45–52. https://doi.org/10.1093/rheumatology/kes243
Im CH, Kim NR, Kang JW, Kim JH, Kang JY, Bae GB, Nam EJ, Kang YM (2014) Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis. Rheumatology. 54(5):808–815. https://doi.org/10.1093/rheumatology/keu376
Ajeganova S, Andersson MLE, Frostegård J, Hafström I (2013) Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 40(12):1958–1966. https://doi.org/10.3899/jrheum.130365
del Rincón I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840. https://doi.org/10.1002/art.11078
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MRF, Raggi P, Stein CM (2003) Premature coronary-artery atherosclerosis in systemic lupus Erythematosus. N Engl J Med 349(25):2407–2415. https://doi.org/10.1056/NEJMoa035611
Schoenfeld SR, Kasturi S, Costenbader KH (2013) The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43(1):77–95. https://doi.org/10.1016/j.semarthrit.2012.12.002
Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12(10):1004–1015. https://doi.org/10.1016/j.autrev.2013.03.013
Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, Greenlee RT (2014) Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 41(4):680–687. https://doi.org/10.3899/jrheum.130874
Wu G-C, Liu H-R, Leng R-X, Li X-P, Li X-M, Pan H-F, Ye DQ (2016) Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev 15(1):22–37. https://doi.org/10.1016/j.autrev.2015.10.002
Lin Y-R, Chou L-C, Chen H-C, Liou T-H, Huang S-W, Lin H-W (2016) Increased risk of dementia in patients with systemic lupus erythematosus: a nationwide population-based cohort study. Arthritis Care Res 68(12):1774–1779. https://doi.org/10.1002/acr.22914
Tomietto P, Annese V, D'Agostini S, Venturini P, La Torre G, De Vita S et al (2007) General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Care Res 57(8):1461–1472. https://doi.org/10.1002/art.23098
Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA (1999) A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 42(4):735–741. https://doi.org/10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L
Gonzales-Portillo F, McIntyre JA, Wagenknecht DR, Williams LS, Bruno A, Biller J (2001) Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 10(5):222–226. https://doi.org/10.1053/jscd.2001.29818
Duarte-García A, Romero-Díaz J, Juárez S, Cicero-Casarrubias A, Fragoso-Loyo H, Núñez-Alvarez C et al (2018) Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with systemic lupus erythematosus and cognitive dysfunction. PLoS One 13(5):e0196487-e. https://doi.org/10.1371/journal.pone.0196487
Ungprasert P, Srivali N, Kittanamongkolchai W (2015) Risk of coronary artery disease in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Transl Med 3(4):51. https://doi.org/10.3978/j.issn.2305-5839.2015.02.05
Peluso R, Caso F, Tasso M, Sabbatino V, Lupoli R, Dario Di Minno MN et al (2019) Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatol 11:143–156. https://doi.org/10.2147/OARRR.S206931
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer's Dement (New York, N Y) 4:575–590. https://doi.org/10.1016/j.trci.2018.06.014
Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease. Neurology. 68(22):1902–1908. https://doi.org/10.1212/01.wnl.0000263217.36439.da
Petersen LE, Baptista TSA, Molina JK, Motta JG, do Prado A, Piovesan DM et al (2018) Cognitive impairment in rheumatoid arthritis: role of lymphocyte subsets, cytokines and neurotrophic factors. Clin Rheumatol 37(5):1171–1181. https://doi.org/10.1007/s10067-018-3990-9
Baptista TSA, Petersen LE, Molina JK, de Nardi T, Wieck A, do Prado A et al (2017) Autoantibodies against myelin sheath and S100β are associated with cognitive dysfunction in patients with rheumatoid arthritis. Clin Rheumatol 36(9):1959–1968. https://doi.org/10.1007/s10067-017-3724-4
Tobinick E, Gross H, Weinberger A, Cohen H (2006) TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 8(2):25
Tobinick EL, Gross H (2008a) Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 5:2. https://doi.org/10.1186/1742-2094-5-2
Tobinick EL, Gross H (2008b) Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 8:27. https://doi.org/10.1186/1471-2377-8-27
Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D et al (2015) Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 84(21):2161–2168. https://doi.org/10.1212/wnl.0000000000001617
Chen K-T, Chen Y-C, Fan Y-H, Lin W-X, Lin W-C, Wang Y-H, Lin L, Chiou JY, Wei JCC (2018) Rheumatic diseases are associated with a higher risk of dementia: a nation-wide, population-based, case-control study. Int J Rheum Dis 21(2):373–380. https://doi.org/10.1111/1756-185x.13246
Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P (2018) Cognitive impairment in rheumatoid arthritis: a systematic review. Arthritis Care Res 70(1):39–52. https://doi.org/10.1002/acr.23243
Vitturi BK, Nascimento BAC, Alves BR, de Campos FSC, Torigoe DY (2019) Cognitive impairment in patients with rheumatoid arthritis. J Clin Neurosci 69:81–87. https://doi.org/10.1016/j.jocn.2019.08.027
Ungprasert P, Wijarnpreecha K, Thongprayoon C (2016) Rheumatoid arthritis and the risk of dementia: a systematic review and meta-analysis. Neurol India 64(1):56–61. https://doi.org/10.4103/0028-3886.173623
Wallin K, Solomon A, Kåreholt I, Tuomilehto J, Soininen H, Kivipelto M (2012) Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis 31:669–676. https://doi.org/10.3233/JAD-2012-111736
Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 58(8):1214–1220. https://doi.org/10.1212/wnl.58.8.1214
Kozora E, Arciniegas DB, Filley CM, West SG, Brown M, Miller D, Grimm A, Devore MD, Wingrove C, Zhang L (2008) Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 59(11):1639–1646. https://doi.org/10.1002/art.24189
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999) Arthritis & Rheumatism. 42(4):599–608. https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
Kozora E, Ellison MC, West S (2004) Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Care Res 51(5):810–818. https://doi.org/10.1002/art.20692
Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, Mustafa A, Su J, Lambiris P, Mosca M, Touma Z (2018) What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum 48(2):240–255. https://doi.org/10.1016/j.semarthrit.02.007
Leslie B, Crowe SF (2018) Cognitive functioning in systemic lupus erythematosus: a meta-analysis. Lupus. 27(6):920–929. https://doi.org/10.1177/0961203317751859
Cannerfelt B, Nystedt J, Jonsen A, Latt J, van Westen D, Lilja A et al (2018) White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 27(7):1140–1149. https://doi.org/10.1177/0961203318763533
Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F et al (2012) Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 7(3):e33824-e. https://doi.org/10.1371/journal.pone.0033824
J Säve-Söderbergh, B E Malmvall, R Andersson, B A Bengtsson (1986) Giant cell arteritis as a cause of death. Report of nine cases. (0098–7484 (Print))
Wilkinson IM, Russell RW (1972) Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 27(5):378–391. https://doi.org/10.1001/archneur.1972.00490170010003
Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84(5):269–276. https://doi.org/10.1097/01.md.0000180042.42156.d1
Alsolaimani RS, Bhavsar SV, Khalidi NA, Pagnoux C, Mandzia JL, Tay K et al (2016) Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol. https://doi.org/10.3899/jrheum.150143
Lariviere D, Sacre K, Klein I, Hyafil F, Choudat L, Chauveheid MP et al (2014) Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine (Baltimore) 93(28):e265. https://doi.org/10.1097/md.0000000000000265
Carlo MD, Becciolini A, Incorvaia A, Beci G, Biggioggero M, Favalli EG et al (2019) SAT0375 Mild cognitive impairment in psoriatic arthritis: prevalence and associated factors. Ann Rheum Dis 78(Suppl 2):1271. https://doi.org/10.1136/annrheumdis-2019-eular.4695
Marek-Józefowicz L, Jaracz M, Placek W, Czajkowski R, Borkowska A (2017) Cognitive impairment in patients with severe psoriasis. Postepy Dermatol Alergol 34(2):120–125. https://doi.org/10.5114/ada.2017.67074
Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, Moretto G, Gambina G, Girolomoni G (2014) Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 228(1):78–85. https://doi.org/10.1159/000357220
Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 163(3):586–592. https://doi.org/10.1111/j.1365-2133.2010.09941.x
Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CEM, Crook MA, Barker JNWN, Smith CH (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154(2):345–352. https://doi.org/10.1111/j.1365-2133.2005.06950.x
Mahley RW, Rall SC (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1(1):507–537. https://doi.org/10.1146/annurev.genom.1.1.507
Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y (2011) Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener 6:69. https://doi.org/10.1186/1750-1326-6-69
Tobinick E (2009) Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs 23(9):713–725. https://doi.org/10.2165/11310810-000000000-00000
Vitturi BK, Suriano ES, Pereira de Sousa AB, Torigoe DY (2020) Cognitive impairment in patients with ankylosing spondylitis. Can J Neurol Sci 47(2):219–225. https://doi.org/10.1017/cjn.2020.14
Baysal O, Durmus B, Ersoy Y, Altay Z, Senel K, Nas K et al (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int 31(6):795–800. https://doi.org/10.1007/s00296-010-1381-x
Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 45(10):1288–1293. https://doi.org/10.1093/rheumatology/kel115
Jang HD, Park JS, Kim DW, Han K, Shin BJ, Lee JC, Choi SW, Suh SW, Yang JH, Park SY, Cho WJ, Hong JY (2019) Relationship between dementia and ankylosing spondylitis: a nationwide, population-based, retrospective longitudinal cohort study. PLoS One 14(1):e0210335. https://doi.org/10.1371/journal.pone.0210335
Dautzenberg L, Jessurum N, Dautzenberg PLJ, Keijsers CJPW (2015) Reversible methotrexate-induced dementia: a case report. J Am Geriatr Soc 63(6):1273–1274. https://doi.org/10.1111/jgs.13517
Chou M-H, Wang J-Y, Lin C-L, Chung W-S (2017) DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity score-matched case–control study. Toxicol Appl Pharmacol 334:217–222. https://doi.org/10.1016/j.taap.2017.09.014
Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, Edwards CJ (2017) Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (N Y) 3(4):612–621. https://doi.org/10.1016/j.trci.2017.10.002
Newby D, Prieto-Alhambra D, Duarte-Salles T, Ansell D, Pedersen L, van der Lei J, Mosseveld M, Rijnbeek P, James G, Alexander M, Egger P, Podhorna J, Stewart R, Perera G, Avillach P, Grosdidier S, Lovestone S, Nevado-Holgado AJ (2020) Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Alzheimers Res Ther 12(1):38. https://doi.org/10.1186/s13195-020-00606-5
Fardet L, Nazareth I, Petersen I (2019) Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study. Ann Rheum Dis 78(2):279–27282. https://doi.org/10.1136/annrheumdis-2018-214016
Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 358(9280):455–460. https://doi.org/10.1016/s0140-6736(01)05623-9
Chou RC, Kane M, Ghimire S, Gautam S, Gui J (2016) Treatment for rheumatoid arthritis and risk of Alzheimer's disease: a nested case-control analysis. CNS Drugs 30(11):1111–1120. https://doi.org/10.1007/s40263-016-0374-z
McGuinness B, Holmes C, Mirakhur A, Kearsley-Fleet L, Vieira R, Watson K, BSRBR-RA Contributors Group, BSRBR-RA Control Centre Consortium, Hyrich K (2018) The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. Int J Geriatr Psychiatry 33(3):556–558. https://doi.org/10.1002/gps.4793
Zhou M, Xu R, Kaelber DC, Gurney ME (2020) Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS One 15(3):e0229819. https://doi.org/10.1371/journal.pone.0229819
McGuinness B (2018) Understanding whether drugs for rheumatoid arthritis can reduce the risk of Alzheimer’s disease. Alzheimer's Society. https://www.alzheimers.org.uk/research/our-research/research-projects/understanding-whether-drugs-rheumatoid-arthritis-can-reduce-risk-alzheimersdisease
Hu J, Feng X, Valdearcos M, Lutrin D, Uchida Y, Koliwad SK, Maze M (2018) Interleukin-6 is both necessary and sufficient to produce perioperative neurocognitive disorder in mice. Br J Anaesth 120(3):537–545. https://doi.org/10.1016/j.bja.2017.11.096
Elcioglu HK, Aslan E, Ahmad S, Alan S, Salva E, Elcioglu OH et al (2016) Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model. Mol Cell Biochem 420(1–2):21–28. https://doi.org/10.1007/s11010-016-2762-6
Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R (2009) Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 48(15):1307–1309. https://doi.org/10.2169/internalmedicine.48.1926
Yamaguchi Y, Furukawa K, Yamamoto T, Takahashi Y, Tanaka K, Takahashi M (2014) Multifocal encephalopathy and autoimmune-mediated limbic encephalitis following tocilizumab therapy. Intern Med 53(8):879–882. https://doi.org/10.2169/internalmedicine.53.0615
Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A (2014) B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int 2014:681678–681614. https://doi.org/10.1155/2014/681678
Cope AP, Schulze-Koops H, Aringer M (2007) The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25(5 Suppl 46):S4–S11
Fuggle NR, Howe FA, Allen RL, Sofat N (2014) New insights into the impact of neuro-inflammation in rheumatoid arthritis. Front Neurosci 8:357. https://doi.org/10.3389/fnins.2014.00357
Chang C, Zhao Y, Song G, She K (2018) Resveratrol protects hippocampal neurons against cerebral ischemia-reperfusion injury via modulating JAK/ERK/STAT signaling pathway in rats. J Neuroimmunol 315:9–14. https://doi.org/10.1016/j.jneuroim.2017.11.015
Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, Guillermier M, Ruiz M, Petit F, Houitte D, Faivre E, Vandesquille M, Aron-Badin R, Dhenain M, Deglon N, Hantraye P, Brouillet E, Bonvento G, Escartin C (2015) The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer’s and Huntington’s diseases. J Neurosci 35(6):2817–2829. https://doi.org/10.1523/jneurosci.3516-14.2015
Cho S-K, Sung Y-K, Kim D, Won S, Choi C-B, Kim T-H et al (2016) Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord 17:333. https://doi.org/10.1186/s12891-016-1185-6
Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Pallavicini FB, Caporali R, Gorla R (2010) Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 38(2):90–96. https://doi.org/10.1007/s12016-009-8142-1
Borren NZ, Ananthakrishnan AN (2019) Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 17(9):1736–43.e4. https://doi.org/10.1016/j.cgh.2018.12.032
Funding
Dr. Raji receives grant support from NIH Grant R01-DA039192.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Ethics approval
Manuscript does not contain clinical studies or patient data.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sood, A., Raji, M.A. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Clin Rheumatol 40, 1221–1231 (2021). https://doi.org/10.1007/s10067-020-05372-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-020-05372-1